Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Certara Inc (NQ: CERT )

10.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 10.46
Bid (Size) 10.16 (1)
Ask (Size) 13.20 (1)
Prev. Close 10.46
Today's Range 10.46 - 10.46
52wk Range 10.35 - 19.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and... 
From Certara
Via GlobeNewswire
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times 
From Certara
Via GlobeNewswire

Performance

YTD
-39.71%
-39.71%
1 Month
-21.23%
-21.23%
3 Month
-24.96%
-24.96%
6 Month
-40.64%
-40.64%
1 Year
-24.75%
-24.75%

More News

Read More
Decoding 4 Analyst Evaluations For Certara
Via Benzinga
Analyst Scoreboard: 4 Ratings For Certara
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Recap: Certara Q3 Earnings
Via Benzinga
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
Certara Launches Phoenix™ Version 8.5 Drug Development Software
From Certara
Via GlobeNewswire
CERT Stock Earnings: Certara Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Certara Reports Second Quarter 2024 Financial Results
From Certara
Via GlobeNewswire
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
From Certara
Via GlobeNewswire
Simulations Plus Stock Drops 15% Despite EPS Beat
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
From Certara
Via GlobeNewswire
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
From Certara
Via GlobeNewswire
Certara to Participate in the Jefferies Global Healthcare Conference
From Certara
Via GlobeNewswire
Certara Appoints New Chief Human Resources Officer & General Counsel
From Certara
Via GlobeNewswire
CERT Stock Earnings: Certara Meets EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Certara Reports First Quarter 2024 Financial Results
From Certara
Via GlobeNewswire
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
From Certara
Via GlobeNewswire
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
From Certara
Via GlobeNewswire
Certara Reports Fourth Quarter 2023 Financial Results
From Certara
Via GlobeNewswire
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
From Certara
Via GlobeNewswire
Tax Season Is Here: Meet The New Federal Program That Can Eat Away At Tax Preparation Companies
Via Benzinga
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
From Certara
Via GlobeNewswire
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
From Certara
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.